TRAIL receptor agonist TLY012 in combination with PD-1 inhibition promotes tumor regression in an immune-competent mouse model of pancreatic ductal adenocarcinoma

Anna D. Louie,Kelsey E. Huntington,Young Lee,Jared Mompoint,Laura Jinxuan Wu,Seulki Lee,Thomas J. Miner,Wafik S. El-Deiry

DOI: https://doi.org/10.1101/2024.08.29.610345

2024-08-30

Abstract:Pancreatic ductal adenocarcinoma (PDAC) has an immunosuppressed, apoptosis-resistant phenotype. TLY012 is a pegylated recombinant Tumor necrosis factor-Related Apoptosis-Inducing Ligand (TRAIL), an orphan drug for chronic pancreatitis and systemic sclerosis. Innate immune TRAIL signaling suppresses cancer. We hypothesized that combination of immune checkpoint-blocking anti-PD-1 antibody and TLY012 would have synergistic anti-tumor efficacy in immune-competent PDAC-bearing mice. PDAC tumor-bearing C57Bl/6 mice treated 10 mg/kg anti-mouse PD-1 antibody twice weekly and 10 mg/kg TLY012 three times weekly had reduced tumor growth and tumor volume at 70 days compared to either drug alone (all p<0.005). B-cell activating factor (BAFF), which promotes PDAC tumors, decreased to 44% of control mice with dual treatment at 7 days and remained decreased at 3 months. Long-term dual treatment showed the highest levels of proinflammatory cytokines interferon gamma (average 5.6 times control level, p=0.046), CCL5 (average 14.1 times control level, p=0.048), and interleukin-3 (IL-3, average 71.1 times control level, p=0.0053). Flow cytometry showed trends toward decreased circulating regulatory T cells, increased NK cells, and a higher proportion of CD8+ T cells within tumors in dual treatment group. In summary, combination of anti-PD-1 and TLY012 prevented growth of PDAC in an immunocompetent mouse model while increasing tumor-infiltrating CD8+ T cells, decreasing circulating T-regulatory cells and altering cytokine expression of CCL5, interferon gamma and IL-3 to promote proinflammatory, antitumor effects. Combining TLY012 and anti-mouse PD-1 creates changes in immune cell and cytokine levels to induce a more proinflammatory immune environment that contributes to decreased PDAC tumor growth.

Cancer Biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the anti - tumor effect of the TRAIL receptor agonist TLY012 in combination with the PD - 1 inhibitor in an immunocompetent pancreatic ductal adenocarcinoma (PDAC) mouse model. Specifically, the study aims to verify the following hypothesis: By modulating the tumor microenvironment, TLY012 can produce a synergistic effect with immune checkpoint blockers (such as PD - 1 antibodies), thereby more effectively inhibiting the growth of PDAC. ### Background Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease characterized by immunosuppression and apoptosis resistance, with a low long - term survival rate. TRAIL (tumor necrosis factor - related apoptosis - inducing ligand) is part of the host immune system and can inhibit transformed cells, virus - infected cells, and cancer and its metastases. TLY012 is a pegylated recombinant TRAIL and has been used as an orphan drug for chronic pancreatitis and systemic sclerosis. ### Research Objectives The researchers hypothesized that the combined use of TLY012 and PD - 1 antibodies could produce a synergistic anti - tumor effect in an immunocompetent PDAC mouse model. Specific objectives include: - **Evaluating the anti - tumor effect of the combined treatment**: Evaluate the effect of the combined treatment by measuring changes in tumor growth and volume. - **Analyzing changes in immune cells and cytokines**: Analyze the impact of the combined treatment on immune cells and cytokines through flow cytometry and serum cytokine level analysis. - **Exploring the mechanism**: Investigate how the combined treatment alters the tumor microenvironment, especially how it increases tumor - infiltrating CD8+ T cells, reduces circulating regulatory T cells, and alters the expression of cytokines such as CCL5, interferon - γ, and IL - 3, thereby promoting an anti - tumor inflammatory response. ### Main Findings - **Anti - tumor effect**: The combined treatment significantly reduced tumor growth and volume, and the effect was better than that of using either drug alone. - **Changes in immune cells**: In the combined treatment group, a decrease in circulating regulatory T cells, an increase in natural killer (NK) cells, and an increase in the proportion of CD8+ T cells within the tumor were observed. - **Changes in cytokines**: In the combined treatment group, the levels of pro - inflammatory cytokines such as interferon - γ, CCL5, and IL - 3 were significantly increased, while the level of the B - cell - activating factor (BAFF) that promotes tumor growth was decreased. ### Conclusions The research results indicate that the combined treatment of TLY012 and PD - 1 antibodies has a significant anti - tumor effect in an immunocompetent PDAC mouse model without obvious toxicity. These findings support further pre - clinical and clinical studies to evaluate the application potential of this new treatment combination in pancreatic cancer and other malignant tumors.

TRAIL receptor agonist TLY012 in combination with PD-1 inhibition promotes tumor regression in an immune-competent mouse model of pancreatic ductal adenocarcinoma

Combined Inhibition Of Tgf- Signaling And The Pd-L1 Immune Checkpoint Is Differentially Effective In Tumor Models

Single Dual-specific Anti-PD-L1/TGF-β Antibody Synergizes with Chemotherapy as Neoadjuvant Treatment for Pancreatic Ductal Adenocarcinoma: a Preclinical Experimental Study

Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors

Combining protein arginine methyltransferase inhibitor and anti-programmed death-ligand-1 inhibits pancreatic cancer progression.

Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo

DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma

CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer

IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer

Cytotoxic chemotherapy potentiates the immune response and efficacy of combination CXCR4/PD-1 inhibition in models of pancreatic ductal adenocarcinoma

Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs

Transforming Growth Factor-Β2 Inhibition in Combination with Interleukin-2 Enhanced T-Cell Mediated Anti-Tumor Activities Via Attenuation of the Fibrotic Reaction in a Humanized Mouse Model of Pancreatic Ductal Adenocarcinoma

IL15 and Anti-PD-1 Augment the Efficacy of Agonistic Intratumoral Anti-CD40 in a Mouse Model with Multiple TRAMP-C2 Tumors

Targeting T cell checkpoints 41BB and LAG3 and myeloid cell CXCR1/CXCR2 results in antitumor immunity and durable response in pancreatic cancer

Anti-IL-8 antibody activates myeloid cells and potentiates the anti-tumor activity of anti-PD-1 antibody in the humanized pancreatic cancer murine model

Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer

Abstract 5515: Combination of recombinant murine IL-12 and anti-PD-1 induced synergistic anti-tumor response

Co-inhibition of the TGF-β Pathway and the PD-L1 Checkpoint by Ph-Responsive Clustered Nanoparticles for Pancreatic Cancer Microenvironment Regulation and Anti-Tumor Immunotherapy.

Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor

PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma

Combined α-programmed death-1 monoclonal antibody blockade and fractionated radiation therapy reduces tumor growth in mouse EL4 lymphoma.